Based on the company's latest reports for March 2026, the current 12-month EPS is $10.93. Davita's earnings per share in 2025 was reported at $10.06, marking a decline from $11.02 in 2024. In the quarterly report ending on Mar 31, 2026, DVA's earnings per share amounted to $2.93.
Davita had an yealy earnings per share of $10.06, showing a decline of 8.7% from $11.02 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was $2.93, showing a 42.9% increase compared to the same quarter last year. The trailing twelve months EPS for DVA is $10.93 as of March 2026. Davita's full-year EPS for 2024 was $11.02, a 44.6% rise compared to the previous year.
In the past 12 months, Davita has recorded an earnings per share growth rate of 42.9% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 18.6% per year. In the last five years, the company had an average annual EPS growth of 9.3%. When assessed over a ten-year period, DVA's average EPS annual growth was 23%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| UHS Universal Health Services Inc | 6.01 | 36.5% | 36.4% | 16.2% |
| THC Tenet Healthcare Corp | 9.33 | -52.7% | 59.6% | 32.7% |
| MD Mednax Inc | 11.42 | 265.5% | 35.6% | N/A |
| DVA Davita Inc | 19.3 | -8.7% | 18.6% | 9.3% |
| LH Laboratory Corp Of America Holdings | 22.76 | 18.6% | -9.1% | -8% |
All data is based on quarterly TTM periods, unless otherwise specified.